IRIS

IRIS Home | Critical Effect Search Results

Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the RfD, RfC, oral slope factor, or inhalation unit risk. Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see Quick Check: Assessments in Development.

Search Filtered by: Critical Effect = "Nervous"
Number of records: 111
Chemical Name CASRN Exposure Route Critical Effect RfD/RfC RfD/RfC Value
Acephate 30560-19-1 Oral Inhibition of brain ChE RFD 4 x 10 -3 mg/kg-day
Acetaldehyde 75-07-0 Inhalation Degeneration of olfactory epithelium RFC 9 x 10 -3 mg/m3
Acetochlor 34256-82-1 Oral Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males RFD 2 x 10 -2 mg/kg-day
Acrylamide 79-06-1 Oral Degenerative nerve changes RFD 2 x 10 -3 mg/kg-day
Acrylamide 79-06-1 Inhalation Degenerative nerve changes RFC 6 x 10 -3 mg/m3
Acrylic acid 79-10-7 Inhalation Degeneration of the nasal olfactory epithelium RFC 1 x 10 -3 mg/m3
Aldicarb 116-06-3 Oral Sweating as clinical sign of AChe inhibition RFD 1 x 10 -3 mg/kg-day
Aldicarb sulfone 1646-88-4 Oral Brain ChE inhibition in females RFD 1 x 10 -3 mg/kg-day
Allyl chloride 107-05-1 Inhalation Functional and histological peripheral neurotoxicity RFC 1 x 10 -3 mg/m3
Baygon 114-26-1 Oral Mild cholinergic symptoms and RBD ChE inhibition RFD 4 x 10 -3 mg/kg-day
Benzidine 92-87-5 Oral Brain cell vacuolization; liver cell alterations in females RFD 3 x 10 -3 mg/kg-day
Biphenthrin 82657-04-3 Oral Tremors RFD 1.5 x 10 -2 mg/kg-day
Bromomethane 74-83-9 Inhalation Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity RFC 5 x 10 -3 mg/m3
Carbofuran 1563-66-2 Oral RBC and plasma cholinesterase inhibition, and testicular and uterine effects RFD 5 x 10 -3 mg/kg-day
Carbon disulfide 75-15-0 Inhalation Peripheral nervous system dysfunction RFC 7 x 10 -1 mg/m3
Chloral hydrate 302-17-0 Oral CNS depression and GI irritation in humans RFD 1 x 10 -1 mg/kg-day
Chlorine cyanide 506-77-4 Oral Weight loss, thyroid effects, and myelin degeneration RFD 5 x 10 -2 mg/kg-day
Chlorine dioxide 10049-04-4 Oral Neurodevelopmental effects RFD 3 x 10 -2 mg/kg-day
Chlorite (sodium salt) 7758-19-2 Oral Neurodevelopmental effects RFD 3 x 10 -2 mg/kg-day
Chlorobenzilate 510-15-6 Oral Decreased stool quantity, food consumption and body weight gains hyperirritability (maternal effects) RFD 2 x 10 -2 mg/kg-day
Chloroprene 126-99-8 Inhalation Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively RFC 2 x 10 -2 mg/m3
Cyanogen bromide 506-68-3 Oral Weight loss, thyroid effects and myelin degeneration RFD 9 x 10 -2 mg/kg-day
Danitol 39515-41-8 Oral Tremors RFD 2.5 x 10 -2 mg/kg-day
2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Oral Neurobehavioral effects RFD 7 x 10 -3 mg/kg-day
Demeton 8065-48-3 Oral ChE inhibition, optic nerve degeneration RFD 4 x 10 -5 mg/kg-day
Dichloroacetic acid 79-43-6 Oral Lesions observed in the testes, cerebrum, cerebellum, and liver. RFD 4 x 10 -3 mg/kg-day
Dichlorvos 62-73-7 Inhalation Decreased brain cholinesterase activity RFC 5 x 10 -4 mg/m3
Dichlorvos 62-73-7 Oral Plasma and RBC ChE inhibition in males and females brain ChE inhibition in males RFD 5 x 10 -4 mg/kg-day
Dimethoate 60-51-5 Oral Brain ChE inhibition RFD 2 x 10 -4 mg/kg-day
2,4-Dimethylphenol 105-67-9 Oral Clinical signs (lethargy, prostration, and ataxia) and hematological changes RFD 2 x 10 -2 mg/kg-day
2,4-Dinitrotoluene 121-14-2 Oral Neurotoxicity, Heinz bodies and biliary tract hyperplasia RFD 2 x 10 -3 mg/kg-day
1,4-Dioxane 123-91-1 Inhalation Atrophy and respiratory metaplasia of the olfactory epithelium RFC 3 x 10 -2 mg/m3
Disulfoton 298-04-4 Oral ChE inhibition, optic nerve degeneration RFD 4 x 10 -5 mg/kg-day
1,4-Dithiane 505-29-3 Oral Nasal olfactory lesions RFD 1 x 10 -2 mg/kg-day
Endrin 72-20-8 Oral Mild histological lesions in liver, occasional convulsions RFD 3 x 10 -4 mg/kg-day
Ethephon 16672-87-0 Oral Plasma ChE inhibition RFD 5 x 10 -3 mg/kg-day
Ethion 563-12-2 Oral Plasma cholinesterase inhibition RFD 5 x 10 -4 mg/kg-day
Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 Oral Neurotoxicity RFD 1 x 10 -5 mg/kg-day
Fenamiphos 22224-92-6 Oral ChE inhibition RFD 2.5 x 10 -4 mg/kg-day
Fonofos 944-22-9 Oral Cholinesterase inhibition, cholinergic symptoms, and increased liver weight RFD 2 x 10 -3 mg/kg-day
2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 Oral Neurobehavioral effects RFD 2 x 10 -4 mg/kg-day
Hexachloroethane 67-72-1 Inhalation Neurotoxicity (tremors and ruffled pelt) RFC 3 x 10 -2 mg/m3
Hexachlorophene 70-30-4 Oral Swollen salivary glands, status spongiosis in brain and optic nerve RFD 3 x 10 -4 mg/kg-day
Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Convulsions in F344 rats RFD 4 x 10 -3 mg/kg-day
1,6-Hexamethylene diisocyanate 822-06-0 Inhalation Degeneration of olfactory epithelium RFC 1 x 10 -5 mg/m3
n-Hexane 110-54-3 Inhalation Peripheral neuropathy (decreased MCV at 12 weeks) RFC 7 x 10 -1 mg/m3
2-Hexanone 591-78-6 Oral Axonal swelling of the peripheral nerve RFD 5 x 10 -3 mg/kg-day
2-Hexanone 591-78-6 Inhalation Motor conduction velocity of the sciatic-tibial nerve RFC 3 x 10 -2 mg/m3
Hydrogen sulfide 7783-06-4 Inhalation Nasal lesions of the olfactory mucosa RFC 2 x 10 -3 mg/m3
Isobutyl alcohol 78-83-1 Oral Hypoactivity and ataxia RFD 3 x 10 -1 mg/kg-day
Malathion 121-75-5 Oral RBC ChE depression RFD 2 x 10 -2 mg/kg-day
Manganese 7439-96-5 Oral CNS effects RFD 1.4 x 10 -1 mg/kg-day
Manganese 7439-96-5 Inhalation Impairment of neurobehavioral function RFC 5 x 10 -5 mg/m3
Mepiquat chloride 24307-26-4 Oral Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects RFD 3 x 10 -2 mg/kg-day
Mercury, elemental 7439-97-6 Inhalation Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction RFC 3 x 10 -4 mg/m3
Merphos 150-50-5 Oral Ataxia, delayed neurotoxicity and weight loss RFD 3 x 10 -5 mg/kg-day
Merphos oxide 78-48-8 Oral Ataxia, delayed neurotoxicity and weight loss RFD 3 x 10 -5 mg/kg-day
Methamidophos 10265-92-6 Oral ChE inhibition RFD 5 x 10 -5 mg/kg-day
Methanol 67-56-1 Inhalation Reduced brain weight in rat pups at 6 weeks of age RFC 2 x 10 1 mg/m3
Methyl chloride 74-87-3 Inhalation Cerebellar lesions RFC 9 x 10 -2 mg/m3
Methyl methacrylate 80-62-6 Inhalation Degeneration/ atrophy of olfactory epithelium (male rats) RFC 7 x 10 -1 mg/m3
Methyl parathion 298-00-0 Oral RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs RFD 2.5 x 10 -4 mg/kg-day
Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 Inhalation Hyperplasia of olfactory epithelium RFC 6 x 10 -4 mg/m3
Methylmercury (MeHg) 22967-92-6 Oral Developmental neuropsychological impairment RFD 1 x 10 -4 mg/kg-day
Methylmercury (MeHg) 22967-92-6 Oral Developmental neuropsychological impairment RFD 1 x 10 -4 mg/kg-day
2-Methylphenol 95-48-7 Oral Decreased body weights and neurotoxicity RFD 5 x 10 -2 mg/kg-day
3-Methylphenol 108-39-4 Oral Decreased body weights and neurotoxicity RFD 5 x 10 -2 mg/kg-day
Naled 300-76-5 Oral Brain ChE inhibition RFD 2 x 10 -3 mg/kg-day
Naphthalene 91-20-3 Inhalation Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively RFC 3 x 10 -3 mg/m3
Nitrobenzene 98-95-3 Inhalation Bronchiolization of the alveoli and olfactory degeneration RFC 9 x 10 -3 mg/m3
2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 Oral Neurobehavioral effects RFD 1 x 10 -4 mg/kg-day
Phosmet 732-11-6 Oral Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition RFD 2 x 10 -2 mg/kg-day
Pirimiphos-methyl 29232-93-7 Oral Transient plasma ChE depression RFD 1 x 10 -2 mg/kg-day
Propham 122-42-9 Oral Increase in male spleen weight and ChE depression in females RFD 2 x 10 -2 mg/kg-day
Propionaldehyde 123-38-6 Inhalation Atrophy of olfactory epithelium RFC 8 x 10 -3 mg/m3
Propylene glycol monomethyl ether (PGME) 107-98-2 Inhalation Mild reversible sedation RFC 2 mg/m3
Pydrin 51630-58-1 Oral Neurological dysfunction RFD 2.5 x 10 -2 mg/kg-day
Selenious acid 7783-00-8 Oral Clinical selenosis RFD 5 x 10 -3 mg/kg-day
Selenium and Compounds 7782-49-2 Oral Clinical selenosis RFD 5 x 10 -3 mg/kg-day
Silver cyanide 506-64-9 Oral Weight loss, thyroid effects, and myelin degeneration RFD 1 x 10 -1 mg/kg-day
Styrene 100-42-5 Inhalation CNS effects RFC 1 mg/m3
2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 Oral Neurobehavioral effects RFD 1 x 10 -4 mg/kg-day
Tetrachloroethylene (Perchloroethylene) 127-18-4 Oral (See Note) RFD 6 x 10 -3 mg/kg-day
Tetrachloroethylene (Perchloroethylene) 127-18-4 Inhalation (See Note) RFC 4 x 10 -2 mg/m3
Tetrachlorovinphos 961-11-5 Oral Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition RFD 3 x 10 -2 mg/kg-day
Tetraethyldithiopyrophosphate 3689-24-5 Oral Depressed RBC and plasma cholinesterase activity RFD 5 x 10 -4 mg/kg-day
Tetrahydrofuran 109-99-9 Inhalation Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) RFC 2 mg/m3
Thiram 137-26-8 Oral Neurotoxicity RFD 5 x 10 -3 mg/kg-day
Toluene 108-88-3 Inhalation Neurological effects in occupationally-exposed workers RFC 5 mg/m3
1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) 76-13-1 Oral Psychomotor impairment RFD 3 x 10 1 mg/kg-day
1,1,1-Trichloroethane 71-55-6 Inhalation Performance on neurobehavioral tests RFC 9 mg/m3
1,1,1-Trichloroethane 71-55-6 Inhalation Performance on neurobehavioral tests RFC 7 mg/m3
1,1,1-Trichloroethane 71-55-6 Inhalation Performance on neurobehavioral tests RFC 7 mg/m3
1,1,1-Trichloroethane 71-55-6 Inhalation Performance on neurobehavioral tests RFC 6 mg/m3
1,1,1-Trichloroethane 71-55-6 Inhalation Performance on neurobehavioral tests RFC 5 mg/m3
1,3,5-Trimethylbenzene 108-67-8 Inhalation Decreased pain sensitivity in male Wistar rats RFC 6 x 10 -2 mg/m3
1,3,5-Trimethylbenzene 108-67-8 Oral Decreased pain sensitivity in male Wistar rats RFD 1 x 10 -2 mg/kg-day
1,2,3-Trimethylbenzene 526-73-8 Oral Decreased pain sensitivity in male Wistar rats RFD 1 x 10 -2 mg/kg-day
1,2,3-Trimethylbenzene 526-73-8 Inhalation Decreased pain sensitivity in male Wistar rats RFC 6 x 10 -2 mg/m3
1,2,3-Trimethylbenzene 526-73-8 Inhalation Decreased pain sensitivity in male Wistar rats RFC 2 x 10 -1 mg/m3
1,2,4-Trimethylbenzene 95-63-6 Inhalation Decreased pain sensitivity in male Wistar rats RFC 6 x 10 -2 mg/m3
1,2,4-Trimethylbenzene 95-63-6 Inhalation Decreased pain sensitivity in male Wistar rats RFC 2 x 10 -1 mg/m3
1,3,5-Trimethylbenzene 108-67-8 Inhalation Decreased pain sensitivity in male Wistar rats RFC 2 x 10 -1 mg/m3
1,2,4-Trimethylbenzene 95-63-6 Oral Decreased pain sensitivity in male Wistar rats RFD 4 x 10 -2 mg/kg-day
1,2,4-Trimethylbenzene 95-63-6 Oral Decreased pain sensitivity in male Wistar rats RFD 1 x 10 -2 mg/kg-day
1,2,3-Trimethylbenzene 526-73-8 Oral Decreased pain sensitivity in male Wistar rats RFD 4 x 10 -2 mg/kg-day
1,3,5-Trimethylbenzene 108-67-8 Oral Decreased pain sensitivity in male Wistar rats RFD 4 x 10 -2 mg/kg-day
Vinyl acetate 108-05-4 Inhalation Nasal epithelial lesions RFC 2 x 10 -1 mg/m3
Xylenes 1330-20-7 Inhalation Impaired motor coordination (decreased rotarod performance) RFC 1 x 10 -1 mg/m3
Zinc cyanide 557-21-1 Oral Weight loss, thyroid effects, and myelin degeneration RFD 5 x 10 -2 mg/kg-day
n-Butanol 71-36-3 Oral Hypoactivity and ataxia RFD 1 x 10 -1 mg/kg-day